Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for JADE201 in Rheumatoid arthritis. The expected timing is based on the latest available company guidance and may change.
Begin first-in-human trial in H1 2026. 03/06/26:- Ph1 RA first-in-human trial expected to start in Q2 2026; interim data anticipated in 2027. 05/07/26:- Ph1 RA trial still expected to start Q2 2026; interim Phase 1 data anticipated in 2027. 05/26/26:- First RA participant dosed in FIH Ph1 single ascending dose trial. Interim FIH data expected in 2027. 08/10/26:- Ph1 RA dosing and interim biomarker-rich data in 2027 reiterated.
Verification
Confirm timing and program details against the company announcement or filing.